Figure 1
HCI2509 impairs cell viability, proliferation and transformation in Type II EC cell lines. (A, B) Dose–response curves showing the effects of 96-hour HCI2509 or medroxyprogesterone 17-acetate (MPA) treatment on cell viability of (A) AN3CA and (B) KLE cells normalized to vehicle controls. EC50s and 95% CI’s were calculated using GraphPad Prism 6.0 and are reported where the R2 > 0.9. Data points are reported as mean and standard deviation (n = 3). (C, D) Proliferation (3 T5) assays showing cell doubling times for (C) AN3CA and (D) KLE cells with vehicle and increasing doses of HCI2509. Data points are reported as mean and standard deviation (n = 3). (E, F) Quantification of colonies formed by (E) AN3CA or (F) KLE cells in soft agar with either vehicle or HCI2509 treatment at varying concentrations. Error bars indicate SD of duplicate assays.